Treatment as Prevention¨

FDA approves Descovy for treatment of HIV

The FDA has approved Descovy, a fixed-dose combination tablet containing emtricitabine and tenofovir alafenamide, for the treatment of HIV, according to the drug’s manufacturer. Descovy (emtricitabine/tenofovir alafenamide [F/TAF]; Gilead Sciences) is administered as a single oral tablet taken daily in combination with other antiretroviral agents. The formulation includes 200 mg emtricitabine and 25 mg tenofovir […]

FDA approves Descovy for treatment of HIV Read More »

Baby boomer Hepatitis C epidemic linked to medical procedures, not risky behaviour

BC Centre for Excellence in HIV/AIDS study finds many baby boomers could have contracted virus in childhood, urges testing. British Columbia researchers have shattered the prevailing stigma that most baby boomers diagnosed with hepatitis C contracted it via risky behaviour. Dr. Julio Montaner and his team at the BC Centre for Excellence in HIV/AIDS partnered

Baby boomer Hepatitis C epidemic linked to medical procedures, not risky behaviour Read More »

Hepatitis C in baby boomers unrelated to risky behaviour, researchers say

TORONTO – Canadian researchers have determined the peak of the hepatitis C epidemic in North America occurred about 15 years earlier than previously believed, suggesting it wasn’t youthful indiscretions that put baby boomers at a high risk for the disease. And that means, say researchers, that all those who belong to the post-Second World War

Hepatitis C in baby boomers unrelated to risky behaviour, researchers say Read More »

Men Are Not Macaques and Other Lessons From Long-Acting PrEP Study

Imagine seeing a patient every eight weeks for a few quick injections into the buttocks that could prevent HIV between appointments. That’s the promise of the ÉCLAIR trial of the investigational integrase strand transfer inhibitor cabotegravir, which had its phase-2 results unveiled at CROI 2016 in February. ÉCLAIR was one of two trials of long-acting

Men Are Not Macaques and Other Lessons From Long-Acting PrEP Study Read More »

Apportioning blame in the North American hepatitis C virus epidemic

A novel investigation into the North American spread of hepatitis C virus permits blame shifting, which the authors Jeffrey Joy and colleagues hope will increase the number of baby boomers who undergo testing. The medical community can now take its share of the responsibility for hepatitis C virus infection in its conversations with the 1945-65

Apportioning blame in the North American hepatitis C virus epidemic Read More »

Baby boomers at risk of hidden hepatitis C, but unrelated to behaviour

TORONTO — Canadian researchers have determined the peak of the hepatitis C epidemic in North America occurred about 15 years earlier than previously believed, suggesting it wasn’t youthful indiscretions that put baby boomers at a high risk for the disease. And that means, say researchers, that all those who belong to the post-Second World War

Baby boomers at risk of hidden hepatitis C, but unrelated to behaviour Read More »

Scroll to Top

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below